Thursday, November 21, 2024 11/21/2024

B Cell Bioinformatic Supplement: HIV Vaccine Trials Network (HVTN)

Award Number: UM1AI068635
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Project Abstract Project Title: B-Cell Bioinformatics and Analytics for the HVTN Discovery Medicine Program This proposal outlines the scientific agenda for the HIV Vaccine Trials Network (HVTN) Statistical and Data Management Center (SDMC) to expand our capacity in carrying out B-cell bioinformatics and analytics work. This effort is aimed at supporting the increasing demands of the rapidly growing HVTN Discovery Medicine Program which is poised to evaluate more than 15 protocols in the current HVTN grant cycle. Given the promising outcome of several broadly neutralizing antibody (bnAb)-inducing vaccine immunogens which have demonstrated initial success in eliciting tier 2 heterologous neutralization antibodies and expanding HIV-1 bnAb precursors, we recognize that it is strategically crucial to evaluate additional vaccine candidates. These candidates should pair prime and boosting immunogens carefully selected to optimally mature B-cell responses towards broad neutralization against HIV. To accomplish this, it is imperative to evaluate and down-select immunogens using assays that provide both cellular- and molecular-level information about evolution of vaccine-induced B-cell repertoires. Addressing these needs necessitates the establishment of robust and standardized computational and analytical pipelines adapted to interrogate B-cell phenotyping (BCP) and B-cell receptor (BCR) sequencing data. The HVTN SDMC has made significant progress since 2020 in developing various aspects of the computational and analytical pipeline that supports its Discovery Medicine Program. However, the SDMC’s funding has become insufficient to meet the critical strategic requirements of the program, particularly those needed to expedite the generation of reports and datasets summarizing BCP and BCR sequencing data to vaccine developers. These reports are critical to accelerate the design and down- selection of boost immunogens required to continue guiding affinity maturation of vaccine-induced B- cells toward neutralization against HIV. These reports are also central to quickly guiding programmatic decisions from the HVTN and NIAID leaderships. This funding shortfall is primarily attributed to the escalating complexity of research studies, the iterative nature of immunogen designs, the increased number of studies in the pipeline, and the expectation that summaries and interpretation of these complex laboratory data should be distributed quickly. Consequently, the HVTN SDMC is seeking supplemental funding for Fiscal Years (FY) 2024 through 2027 to bolster the success of the HVTN Discovery Medicine Program.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $32,323,449 )
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	006	19	8/14/2024	NON-COMPETING CONTINUATION	$0
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	005	19	4/18/2024	NON-COMPETING CONTINUATION	$0
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	007	19	8/14/2024	SUPPLEMENT FOR EXPANSION	$330,961
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	19	11/16/2023	NON-COMPETING CONTINUATION	$15,996,245
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	004	19	4/4/2024	NON-COMPETING CONTINUATION	$15,996,243
2024	2023	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	18	10/25/2023	SUPPLEMENT FOR EXPANSION	$0
2024	2023	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	003	18	12/1/2023	SUPPLEMENT FOR EXPANSION	$0
2024	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	002	17	12/1/2023	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $32,323,449

Issue Date FY: 2023 ( Subtotal = $40,855,833 )
2023	2023	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	009	18	5/2/2023	SUPPLEMENT FOR EXPANSION	$12,647,369
2023	2023	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	010	18	6/20/2023	NON-COMPETING CONTINUATION	$2,268,154
2023	2023	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	008	18	3/1/2023	NON-COMPETING CONTINUATION	$26,241,944
2023	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	16	11/30/2022	SUPPLEMENT FOR EXPANSION	-$241,853
2023	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	012	17	9/18/2023	SUPPLEMENT FOR EXPANSION	-$205
2023	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	006	16	2/7/2023	NON-COMPETING CONTINUATION	-$5,436,127
2023	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	011	17	9/11/2023	SUPPLEMENT FOR EXPANSION	-$59,576
2023	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	002	16	12/19/2022	NON-COMPETING CONTINUATION	$0
2023	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	16	12/13/2022	NON-COMPETING CONTINUATION	$0
2023	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	003	17	1/11/2023	SUPPLEMENT FOR EXPANSION	$0
2023	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	007	17	2/7/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$6,516,622
2023	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	004	14	2/7/2023	SUPPLEMENT FOR EXPANSION	$0
2023	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	005	15	2/7/2023	COMPETING CONTINUATION	-$1,080,495
														Subtotal = $40,855,833

Issue Date FY: 2022 ( Subtotal = $48,014,803 ) (Continued on the next page)
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	017	17	6/7/2022	SUPPLEMENT FOR EXPANSION	$318,803
2022	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	006	16	3/28/2022	SUPPLEMENT FOR EXPANSION	$1,011,819
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	027	17	8/22/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$7,147,272
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	011	17	5/27/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$14,313,000
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	020	17	6/10/2022	SUPPLEMENT FOR EXPANSION	$419,442
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	019	17	6/9/2022	SUPPLEMENT FOR EXPANSION	$234,860
2022	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	002	16	12/1/2021	NON-COMPETING CONTINUATION	$5,436,127
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	013	17	6/1/2022	SUPPLEMENT FOR EXPANSION	$1,846,794
2022	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	010	16	5/27/2022	NON-COMPETING CONTINUATION	$0
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	021	17	6/13/2022	SUPPLEMENT FOR EXPANSION	$453,649
2022	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	005	16	3/21/2022	SUPPLEMENT FOR EXPANSION	$818,451
2022	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	028	16	9/19/2022	SUPPLEMENT FOR EXPANSION	$0
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	018	17	6/8/2022	SUPPLEMENT FOR EXPANSION	$260,795
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	014	17	6/2/2022	SUPPLEMENT FOR EXPANSION	$477,868
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	012	17	5/31/2022	SUPPLEMENT FOR EXPANSION	$14,844,618
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	016	17	6/6/2022	SUPPLEMENT FOR EXPANSION	$293,711
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	015	17	6/3/2022	SUPPLEMENT FOR EXPANSION	$439,437
2022	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	007	16	3/29/2022	SUPPLEMENT FOR EXPANSION	$1,334,886
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	004	15	1/21/2022	SUPPLEMENT FOR EXPANSION	$0
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	15	10/21/2021	SUPPLEMENT FOR EXPANSION	$0
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	023	15	6/24/2022	SUPPLEMENT FOR EXPANSION	$0
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	15	10/21/2021	SUPPLEMENT FOR EXPANSION	$0
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	026	15	8/8/2022	SUPPLEMENT FOR EXPANSION	$0
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	022	15	6/24/2022	SUPPLEMENT FOR EXPANSION	$0
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	009	15	5/19/2022	COMPETING CONTINUATION	$1,287,974
2022	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	030	15	9/23/2022	SUPPLEMENT FOR EXPANSION	-$1,636,729
Grand Total All Awards = $310,901,837

Page 1 of 3 (116 items)12 3

Top

All Categories

About

Search

Reports

Data Submission

Award Information

B Cell Bioinformatic Supplement: HIV Vaccine Trials Network (HVTN)

Award Number: UM1AI068635

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer